Premium
Treatment‐related deaths in second complete remission in childhood acute myeloid leukaemia
Author(s) -
MolgaardHansen Lene,
Möttönen Merja,
Glosli Heidi,
Jónmundsson Guðmundur K.,
Abrahamsson Jonas,
Hasle Henrik
Publication year - 2011
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2010.08554.x
Subject(s) - medicine , hematology , myeloid leukaemia , disease , haematopoiesis , pediatrics , hematopoietic stem cell transplantation , complete remission , prospective cohort study , cohort , myeloid , stem cell , oncology , chemotherapy , genetics , biology
Summary The frequency and causes of treatment‐related deaths (TRD) in second complete remission (CR2) in acute myeloid leukaemia (AML) were investigated in a historical, prospective cohort study of 429 children included in the Nordic Society of Paediatric Haematology and Oncology (NOPHO)‐AML‐88 and ‐93 trials. Relapse occurred in 158 children (39%). Seventeen (18%) of the 96 patients entering CR2 suffered TRD. The main causes were infection (59%) and complications from graft‐ versus ‐host disease (22%). Fourteen (82%) of 17 TRDs occurred in children undergoing haematopoietic stem cell transplantations (HSCT). Optimal supportive care after HSCT is essential, and studies on risk factors for TRD are needed.